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Background: Survivin is a member of Inhibitor of Apoptosis (IAP) 
family and considered to play a signiﬁcant role of tumorigenesis and 
proliferation. Over expression of survivin was reported in several can-
cers including non-small cell lung cancer (NSCLC), and these reports 
suggested there is correlation between survivin expression and patient’s 
prognosis. The purpose of this report is to clarify this relationship in 
NSCLC.
Methods: We examined 100 NSCLC tissues resected from 2000 Oct. 
to 2004 Dec. in Tohoku University Hospital. The 100 patients consisted 
of 71 men and 29 women. The median age was 66.2 (range 30-80). The 
histology and pathological staging were following: adenocarcinoma 71, 
squamous cell carcinoma 29, IA 35, IB 24, IIA 5, IIB 10, IIIA 16, IIIB 
9, IV 1. We assessed the expression of survivin, p53, NF kappa B, and 
Bcl-2 by immunohistochemistry. These proteins were considered to 
have correlation with survivin. Moreover mRNA expression of survivin 
variants was also examined by real time polymerase chain reaction 
(PCR). PCR primers were set for wild-type survivin, survivin-deltaEx3, 
survivin-2B, survivin-3B, and survivin-2alpha. 
Results: The number of cytoplasmic survivin-positive tissue was 88, 
and nuclear survivin-positive tissue was 40 (both positive was 36). We 
have 57 p53 positive, 67 NF kappa B positive, and 12 Bcl-2 positive 
tissues. The results for real time PCR will be reported.
Conclusions: We will analyse these data and show the relationship 
between expression of apoptosis related proteins including survivin and 
prognosis or stage. 
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Background: Our aim was to determine the genes predictive for re-
lapse-free and overall survival in stage I-II NSCLC. 
Methods: We analyzed the gene expression proﬁles in lung cancer 
specimens collected from 70 NSCLC patients (pts) who underwent 
curative pulmonary resection between 1999 and 2004. There were 54 
men and 16 women aged 37-77 yrs (median 62.5 yrs), 45 with squa-
mous cell ca, 22 with adenoca and 3 with large cell ca. Eight pts were 
staged pT1, 59 pT2 and 3 pT3; there were 49 and 21 pN0 and pN1 pts, 
respectively. 30 pts had a relapse and 32 pts died (median follow-up 36 
months). Samples of tumor tissue were collected intraoperatively and 
snap-frozen, total RNA was isolated and gene expression proﬁling was 
carried out by Affymetrix HG-U133 2.0 Plus oligonucleotide microar-
ray. Samples were pre-processed with RMA algorithm, gene selection 
was carried out by Support Vector Machines and Bayesian Compound 
Covariate Classiﬁer, using own procedures and BRB-Array software 
developed by Simon and Peng Lam. Survival time prediction was car-
ried out by method developed by Bair and Tibshirani (PLoS Biology 
2004).
Results: Based on the microarray gene expression proﬁling, the relapse 
could be predicted with 75% speciﬁcity and 53% sensitivity (positive 
predictive value [PPV] 62%, negative predictive value [NPV] 68%). 
The classiﬁer, obtained by cross-validation of 70-sample dataset, 
consisted of 170 transcripts. Further gene selection was based on the 
prediction of the relapse-free survival: 1919 genes, selected by ﬁtting 
Cox proportional hazard model (p<0.05) and further used to predict 
survival by 4 principal components, distinguished between pts with 
high and low risk of relapse (p<0.05, log-rank test). The prediction 
of death was possible with 66% speciﬁcity and 57% sensitivity (PPV 
53%, NPV 70%), but the distinction between high- and low-risk pts 
was signiﬁcantly weaker than based on lymph node involvement (N0 
vs. N1). Thus, for the ﬁnal selection of genes this clinical variable was 
incorporated into the model as a covariate. 
Conclusion: Prediction of the risk of relapse in stage I-II NSCLC 
based on the gene expression proﬁle is feasible, with NPV of 68%. 
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Purpose: Alterations in apoptosis-related proteins and DNA damage 
repair proteins are associated with resistance to chemotherapy or radio-
therapy, which is the most important cause of treatment failure in small 
cell lung cancer (SCLC). 
Patients and Methods: Pretreatment tumor biopsy specimens from 
77 patients with SCLC (limited stage: 40, extensive stage: 37) were 
analyzed for p53, bcl-2, bax and ERCC1 expression by immunohisto-
chemistry. All patients were treated with platinum-based doublets. The 
most commonly used regimen was etoposide/cisplatin (50 patients). In 
patients with limited stage SCLC, thoracic irradiation was performed 
either concurrently with chemotherapy or sequentially.
Results: High expression of p53, bcl-2, bax and ERCC1 was observed 
in 40 (52%), 72 (94%), 38 (49%) and 13 (17%) patients, respectively. 
High expression of ERCC1 was associated with poor OS (1-year, 23% 
vs. 53%; p=0.026). A signiﬁcant correlation between high expression of 
ERCC1 and poor outcome was observed only in patients with limited 
stage SCLC (p=0.017). High expression of p53, bcl-2 and bax was not 
correlated with patient outcome. Multivariate analysis showed that 
extensive stage (p=0.006) and male gender (p=0.009) were independent 
predictors of poor OS, while high expression of ERCC1 failed to reach 
statistical signiﬁcance despite a trend (p=0.057). In limited stage pa-
